{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:39:32Z","timestamp":1791916772132,"version":"4.3.4"},"reference-count":134,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH372"],"award-info":[{"award-number":["ZR2022QH372"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.heliyon.2023.e22905","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T18:13:22Z","timestamp":1701281602000},"page":"e22905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of CD47 in non-neoplastic diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e22905_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1083\/jcb.123.2.485","article-title":"Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding","volume":"123","author":"Lindberg","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103939","article-title":"Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRP\u03b1-based cancer therapy","volume":"184","author":"Olaoba","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib3","series-title":"Targeting CD47 as a Therapeutic Strategy: A Common Bridge in the Therapy of COVID-19-Related Cancers","author":"Zandi","year":"2023"},{"key":"10.1016\/j.heliyon.2023.e22905_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/614619","article-title":"CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg","year":"2013","journal-title":"ISRN Hematol"},{"key":"10.1016\/j.heliyon.2023.e22905_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14728222.2013.733699","article-title":"Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47","volume":"17","author":"Soto-Pantoja","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.heliyon.2023.e22905_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/1042819042000201989","article-title":"Role of CD47 in erythroid cells and in autoimmunity","volume":"45","author":"Oldenborg","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2023.e22905_bib8","first-page":"715","article-title":"Molecular pathology of lung cancer: key to personalized medicine","volume":"41","author":"Cheng","year":"2012","journal-title":"Chinese J. Pathol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/cam4.3768","article-title":"An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity","volume":"10","author":"Wang","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib10","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.3390\/ijms22084062","article-title":"Thrombospondin-1 CD47 signalling: from mechanisms to medicine","volume":"22","author":"Kale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib11","doi-asserted-by":"crossref","first-page":"40156","DOI":"10.1074\/jbc.M104138200","article-title":"The role of CD47 in neutrophil transmigration","volume":"276","author":"Liu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e22905_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/138945008785909310","article-title":"CD47 in the immune response: role of thrombospondin and SIRP-\u03b1 reverse signaling","volume":"9","author":"Sarfati","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.heliyon.2023.e22905_bib14","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.4049\/jimmunol.162.12.7031","article-title":"CD47 signals T cell death","volume":"162","author":"Pettersen","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib15","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M500922200","article-title":"CD47 augments fas\/CD95-mediated apoptosis","author":"Manna","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib16","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1523\/JNEUROSCI.3981-06.2006","article-title":"CD47 promotes neuronal development through Src- and FRG\/Vav2-mediated activation of Rac and Cdc42","volume":"26","author":"Murata","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuron.2018.09.017","article-title":"CD47 protects synapses from excess microglia-mediated pruning during development","volume":"100","author":"Lehrman","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.heliyon.2023.e22905_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP <scp>\u03b1<\/scp>) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nri1859","article-title":"The SIRP family of receptors and immune regulation","volume":"6","author":"Barclay","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib20","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.4049\/jimmunol.175.12.7781","article-title":"Signal regulatory proteins in the immune system","volume":"175","author":"van Beek","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib21","first-page":"2130","article-title":"CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1","volume":"30","author":"Vernon-Wilson","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.heliyon.2023.e22905_bib23","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2004-07-2823","article-title":"Adhesion of human T cells to antigen-presenting cells through SIRP\u03b22-CD47 interaction costimulates T-cell proliferation","volume":"105","author":"Piccio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e22905_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.2001019","article-title":"Novel SIRP\u03b1 antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells","volume":"206","author":"Andrejeva","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcdb.2023.05.008","article-title":"Emerging functions of thrombospondin-1 in immunity","volume":"155","author":"Kaur","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1074\/jbc.M804860200","article-title":"Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses","volume":"284","author":"Isenberg","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib27","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1210\/en.2005-0532","article-title":"Modulation of angiogenesis during adipose tissue development in murine models of obesity","volume":"146","author":"Voros","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.heliyon.2023.e22905_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098358","article-title":"CD47-Independent effects mediated by the TSP-derived 4N1K peptide","volume":"9","author":"Leclair","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e22905_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103024","article-title":"The CIS association of CD47 with integrin Mac-1 regulates macrophage responses by stabilizing the extended integrin conformation","volume":"299","author":"Podolnikova","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12265","article-title":"Single vesicle analysis of CD47 association with integrins and tetraspanins on extracellular vesicles released by T lymphoblast and prostate carcinoma cells","volume":"11","author":"Kaur","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.heliyon.2023.e22905_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e22905_bib32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI70391","article-title":"Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis","volume":"124","author":"Kojima","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2023.e22905_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e22905_bib34","first-page":"413","article-title":"CD47-Blocking antibodies and atherosclerosis, JACC basic to transl","volume":"1","author":"Ryan","year":"2016","journal-title":"Sci"},{"key":"10.1016\/j.heliyon.2023.e22905_bib35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJMc2029834","article-title":"Effect of CD47 blockade on vascular inflammation","volume":"384","author":"Jarr","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation","volume":"62","author":"Tawakol","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2023.e22905_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-019-0619-3","article-title":"Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis","author":"Flores","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib39","doi-asserted-by":"crossref","first-page":"15818","DOI":"10.1073\/pnas.2006348117","article-title":"Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s40425-019-0812-9","article-title":"Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.heliyon.2023.e22905_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14802","article-title":"A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer","author":"Betancur","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e22905_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0812-9","article-title":"Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.heliyon.2023.e22905_bib43","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.4049\/jimmunol.2100903","article-title":"CD47 promotes autoimmune valvular carditis by impairing macrophage efferocytosis and enhancing cytokine production","volume":"208","author":"Meier","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib44","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib45","article-title":"cGMP signaling and vascular smooth muscle cell plasticity","author":"Lehners","year":"2018","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.heliyon.2023.e22905_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s44161-022-00023-x","article-title":"The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis","volume":"1","author":"Jarr","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s44161-022-00038-4","article-title":"Statins boost the macrophage eat-me signal to keep atherosclerosis at bay","volume":"1","author":"Eberhardt","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"issue":"2022","key":"10.1016\/j.heliyon.2023.e22905_bib48","article-title":"Jeffrey M. Hoeg award lecture: defining the role of efferocytosis in cardiovascular disease: a focus on the CD47 (cluster of differentiation 47) Axis","volume":"42","author":"Jarr","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104594","article-title":"Blockade of CD47 function attenuates restenosis by promoting smooth muscle cell efferocytosis and inhibiting their migration and proliferation","volume":"299","author":"Govatati","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrcardio.2016.216","article-title":"Advances in new therapeutic targets for atherosclerosis","volume":"14","author":"Tang","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biomaterials.2016.02.008","article-title":"Enhanced biocompatibility of CD47-functionalized vascular stents","volume":"87","author":"Slee","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.heliyon.2023.e22905_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tins.2020.01.003","article-title":"Astrocytes and microglia: in sickness and in health","volume":"43","author":"Vainchtein","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","article-title":"Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma","volume":"116","author":"Hutter","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e22905_bib55","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/awv066","article-title":"Roles of microglia in brain development, tissue maintenance and repair","volume":"138","author":"Michell-Robinson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2023.e22905_bib56","doi-asserted-by":"crossref","first-page":"43245","DOI":"10.1074\/jbc.M406733200","article-title":"Neuronal roles of the integrin-associated protein (IAP\/CD47) in developing cortical neurons","volume":"279","author":"Numakawa","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib57","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1523\/JNEUROSCI.3981-06.2006","article-title":"CD47 promotes neuronal development through Src- and FRG\/Vav2-Mediated activation of rac and Cdc42","volume":"26","author":"Murata","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archneurol.2007.19","article-title":"Neurological disorders: public health challenges","volume":"65","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neulet.2016.12.006","article-title":"CD47 deficiency improves neurological outcomes of traumatic brain injury in mice","volume":"643","author":"Zhao","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.heliyon.2023.e22905_bib60","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1161\/ATVBAHA.113.301903","article-title":"Novel role of CD47 in rat microvascular endothelium, arterioscler","volume":"33","author":"Martinelli","year":"2013","journal-title":"Thromb. Vasc. Biol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neulet.2016.12.006","article-title":"CD47 deficiency improves neurological outcomes of traumatic brain injury in mice","volume":"643","author":"Zhao","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.heliyon.2023.e22905_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2014.06.003","article-title":"Brain CD47 expression in a swine model of intracerebral hemorrhage","volume":"1574","author":"Zhou","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.nbd.2010.12.010","article-title":"CD47 knockout mice exhibit improved recovery from spinal cord injury","volume":"42","author":"Myers","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.heliyon.2023.e22905_bib64","series-title":"Enhancement of Hematoma Clearance with CD47 Blocking Antibody in Experimental Intracerebral Hemorrhage, Stroke","author":"Jing","year":"2019"},{"key":"10.1016\/j.heliyon.2023.e22905_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s12975-019-00745-4","article-title":"CD47 blocking antibody accelerates hematoma clearance after intracerebral hemorrhage in aged rats","author":"Tao","year":"2020","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12974-019-1516-2","article-title":"Neuroinflammation: friend and foe for ischemic stroke","volume":"16","author":"Jayaraj","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.heliyon.2023.e22905_bib67","article-title":"The mechanism of CD47-dependent killing of T cells: heterotrimeric gi-dependent inhibition of protein kinase A","author":"Manna","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib68","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1471-4159.2008.05777.x","article-title":"Role of oxidative stress and caspase 3 in CD47-mediated neuronal cell death","volume":"108","author":"Xing","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.heliyon.2023.e22905_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.22076","article-title":"Neurovascular effects of CD47 signaling: promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro","author":"Xing","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib70","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s11064-010-0159-6","article-title":"Induction of vascular endothelial growth factor and matrix metalloproteinase-9 via CD47 signaling in neurovascular cells","volume":"35","author":"Xing","year":"2010","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer's disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.heliyon.2023.e22905_bib72","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e22905_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00233","article-title":"Microglia in alzheimer disease: well-known targets and new opportunities","volume":"11","author":"Hemonnot","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib74","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","article-title":"A cell surface receptor complex for fibrillar \u03b2-amyloid mediates microglial activation","volume":"23","author":"Bamberger","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib75","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JAD-2011-101014","article-title":"Microglia demonstrate age-dependent interaction with amyloid-\u03b2 fibrils","volume":"25","author":"Floden","year":"2011","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.heliyon.2023.e22905_bib76","first-page":"1","article-title":"A conditionally releasable \u201cdo not eat me\u201d CD47 signal facilitates microglia-targeted drug delivery for the treatment of Alzheimer's disease","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.heliyon.2023.e22905_bib77","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41422-019-0177-0","article-title":"Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRP\u03b1-CD47 axis","volume":"29","author":"Wu","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP\u03b1 axis and a target for cancer immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib79","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.01076","article-title":"From erythroblasts to mature red blood cells: organelle clearance in mammals","volume":"8","author":"Moras","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib81","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41467-020-20479-4","article-title":"Rhythmic glucose metabolism regulates the redox circadian clockwork in human red blood cells","volume":"12","author":"Ch","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e22905_bib82","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0006-3495(02)75210-7","article-title":"Extreme pathway analysis of human red blood cell metabolism","volume":"83","author":"Wiback","year":"2002","journal-title":"Biophys. J."},{"key":"10.1016\/j.heliyon.2023.e22905_bib83","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1710776114","article-title":"Localized CD47 blockade enhances immunotherapy for murine melanoma","volume":"114","author":"Ingram","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2023.e22905_bib85","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.7150\/thno.72310","article-title":"Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRP\u03b1 signal","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.heliyon.2023.e22905_bib86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/alz.12461","article-title":"Committee on high-quality Alzheimer's disease studies (CHADS) consensus report","volume":"18","author":"Jicha","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.heliyon.2023.e22905_bib87","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00882-9","article-title":"Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD\u2014VIVIAD","volume":"13","author":"Vijverberg","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.heliyon.2023.e22905_bib88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.stem.2021.11.003","article-title":"Relayed signaling between mesenchymal progenitors and muscle stem cells ensures adaptive stem cell response to increased mechanical load","volume":"29","author":"Kaneshige","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.heliyon.2023.e22905_bib89","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.stem.2022.10.009","article-title":"Elevated CD47 is a hallmark of dysfunctional aged muscle stem cells that can be targeted to augment regeneration","volume":"29","author":"Porpiglia","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.heliyon.2023.e22905_bib90","article-title":"Thrombospondin-1 in maladaptive aging responses: a concept whose time has come","volume":"318","author":"Isenberg","year":"2020","journal-title":"Am. J. Physiol. - Cell Physiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib91","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1152\/japplphysiol.00979.2013","article-title":"Angiogenic response to passive movement and active exercise in individuals with peripheral arterial disease","volume":"115","author":"Hoier","year":"2013","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib92","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1113\/expphysiol.2012.067967","article-title":"Intense intermittent exercise provides weak stimulus for vascular endothelial growth factor secretion and capillary growth in skeletal muscle","volume":"98","author":"Hoier","year":"2013","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13250","article-title":"Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion","volume":"7","author":"Sacco","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e22905_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add2387","article-title":"A metabolic role for CD47 in pancreatic \u03b2 cell insulin secretion and islet transplant outcomes","volume":"15","author":"Ghimire","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib95","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2010.01.002","article-title":"Implication of the CD47 pathway in autoimmune diabetes","volume":"35","author":"Dugas","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.heliyon.2023.e22905_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.heliyon.2023.e22905_bib97","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ana.21220","article-title":"Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions","volume":"62","author":"Koning","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib98","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrneurol.2010.179","article-title":"The emerging role of microRNAs in multiple sclerosis","volume":"7","author":"Junker","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib100","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood.V99.10.3500","article-title":"Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice","volume":"99","author":"Oldenborg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e22905_bib101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.heliyon.2023.e22905_bib102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/antib8040057","article-title":"IgA: structure, function, and developability","volume":"8","author":"de Sousa-Pereira","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.heliyon.2023.e22905_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib104","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1\u2013CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib105","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e22905_bib106","series-title":"Anti-Sirp\u03b1 Antibodies as a Potential New Tool for Cancer Immunotherapy","author":"Yanagita","year":"2017"},{"key":"10.1016\/j.heliyon.2023.e22905_bib107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.heliyon.2023.e22905_bib108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.heliyon.2023.e22905_bib109","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRP\u03b1 \u201cdon't eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","author":"van Bommel","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2023.e22905_bib110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-020-0121-2","article-title":"The identification of a CD47-blocking \u201chotspot\u201d and design of a CD47\/PD-L1 dual-specific antibody with limited hemagglutination","volume":"5","author":"Shi","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.heliyon.2023.e22905_bib111","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.immuni.2020.07.008","article-title":"CD47 ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis","volume":"53","author":"Morrissey","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2023.e22905_bib112","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.19.00121","article-title":"Signaling regulatory protein (SIRP)a-CD47 blockade joins the ranks of immune checkpoint inhibition","volume":"37","author":"Veillette","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib113","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.heliyon.2023.e22905_bib114","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e22905_bib115","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e22905_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110255","article-title":"The CD47-SIRP\u03b1 axis is a promising target for cancer immunotherapies","volume":"120","author":"Hao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib117","series-title":"Preliminary Results of a Phase I, First-In-Human, Dose Escalation Study of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors","author":"Meng","year":"2023"},{"key":"10.1016\/j.heliyon.2023.e22905_bib118","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41375-022-01805-9","article-title":"IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRP\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRP\u03b1 interaction and Fc\u0263R engagement by simultaneously binding to CD47","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e22905_bib119","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.trecan.2023.04.006","article-title":"Targeting phagocytosis to enhance antitumor immunity","volume":"9","author":"Huntoon","year":"2023","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.heliyon.2023.e22905_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114865","article-title":"Molecular imaging of innate immunity and immunotherapy","author":"Xia","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2023.e22905_bib121","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e22905_bib122","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134728","article-title":"Targeting macrophage checkpoint inhibitor SIRP\u03b1 for anticancer therapy","volume":"5","author":"Liu","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.heliyon.2023.e22905_bib123","article-title":"Potential role of CD47-directed bispecific antibodies in cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib124","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current challenges in cancer treatment","volume":"38","author":"Zugazagoitia","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.heliyon.2023.e22905_bib125","first-page":"299","article-title":"Cancer immunology for the clinician","volume":"13","author":"Weiner","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2023.e22905_bib126","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.heliyon.2023.e22905_bib127","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1517\/14740338.2013.795944","article-title":"Cancer immunotherapies, their safety and toxicity","volume":"12","author":"Alatrash","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.heliyon.2023.e22905_bib128","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.heliyon.2023.e22905_bib129","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood-2008-01-134429","article-title":"Endothelial CD47 interaction with SIRP\u03b3 is required for human T-cell transendothelial migration under shear flow conditions in vitro","volume":"112","author":"Stefanidakis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e22905_bib130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRP\u03b1 \u201cdon't eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","volume":"7","author":"van Bommel","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2023.e22905_bib131","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/blood-2022-169171","article-title":"First-in-Human (FIH) study of the fully-human kappa-lambda CD19\/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma","volume":"140","author":"Hawkes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e22905_bib132","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood-2021-150570","article-title":"The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G protein-coupled receptor EBI2\/gpr183","volume":"138","author":"Normant","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e22905_bib133","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.heliyon.2023.e22905_bib134","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.omto.2022.02.019","article-title":"Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther. - Oncolytics."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023101137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023101137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:16:35Z","timestamp":1774952195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023101137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":134,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2405844023101137"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22905","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of CD47 in non-neoplastic diseases","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e22905"}}